Halozyme Therapeutics, Inc. (NASDAQ:HALO) company on Apr. 9 announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. According to the FDA, this action was being taken in view of the company’s recent decision to temporarily halt enrollment and dosing of PEGPH20 in the Phase 2 trial. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares after opening at $8.07 moved to $8.16 on last trade day and at the end of the day closed at $7.49. Company price to sales ratio in past twelve months was calculated as 16.95 and price to cash ratio as 12.99. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a negative weekly performance of -35.38%.
Ventrus Biosciences, Inc. (NASDAQ: VTUS) announced that, in response to a request from the company, the U.S. Food and Drug Administration (FDA) has scheduled a Type B pre-NDA meeting on Thursday, June 19, 2014 at which the company will seek guidance on its planned new drug application (NDA) for DOLIZEM (diltiazem hydrochloride cream) in anal fissures. Ventrus would expect to file an NDA in the second half of 2014 with an anticipated PDUFA date in the second half of 2015 if there is a positive outcome of this pre-NDA meeting. Ventrus Biosciences Inc (NASDAQ:VTUS) shares advanced 1.65% in last trading session and ended the day on $1.23. VTUS return on equity ratio is recorded as -60.40% and its return on assets is -55.60%. Ventrus Biosciences Inc(NASDAQ:VTUS) yearly performance is -56.38%.
PharmAthene, Inc. (AMEX:PIP) announced that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax program. Pharm Athene, Inc. (NYSEMKT:PIP) shares moved down -7.10% in last trading session and was closed at $1.44, while trading in range of $1.43 – 1.52. Pharm Athene, Inc. (NYSEMKT:PIP) year to date (YTD) performance is -22.58%.
Zacks started coverage on shares of Ignyta Inc (NASDAQ:RXDX) in a research report issued on Wednesday, Analyst Ratings News reports. The firm set a “hold” rating on the stock. Ignyta Inc (NASDAQ:RXDX) weekly performance is -19.30%. On last trading day company shares ended up $57. Ignyta Inc (NASDAQ:RXDX) distance from 50-day simple moving average (SMA50) is -42.69%. Analysts mean target price for the company is $20.00.
Leave a Reply